Verrica Pharmaceuticals schedules conference call to discuss Q2 results, corporate updatePUBT·17 hours agoVRCA+1.54%
Fed Rate Jitters Send Ripples Through Fringe Assets and Yield-Sensitive ETFsGlobal Report·20 hours agoOPI+5.33%VRCA+1.54%
Verrica signs exclusive deal with Medomie to market Ycanth in IsraelPUBT·Jul 21 at 07:07 AMVRCA+1.54%
H.C. Wainwright Sticks to Their Buy Rating for Verrica Pharmaceuticals (VRCA)Tip Ranks·Jun 22 at 09:15 AMVRCA+1.54%
Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts | VRCA Stock NewsStockTitan·Jun 21 at 11:05 PMVRCA+1.54%4551
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference | VRCA Stock NewsStockTitan·May 27 at 11:05 PMVRCA+1.54%IBB+0.76%
Verrica Pharmaceuticals | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 5.023 MEarnings Watch·May 12 at 03:24 PMVRCA+1.54%
Verrica Pharmaceuticals | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 5.023 MEarnings Watch·May 12 at 03:16 PMVRCA+1.54%
Verrica To Present Positive Phase 2 Data For VP-315 In Treating Basal Cell Carcinoma At SID Meetingnasdaq·May 6 at 04:50 AMVRCA+1.54%ARKG+4.69%
